Largest Shareholder Calls for Neuronetics to Sell TMS Unit, Citing 5-7x Upside
STIM has more than doubled off its 52-week low of $0.8.
Summary
Activist investor Jorey Chernett, Neuronetics' largest independent shareholder with a 14.12% stake, has formally demanded the company's board initiate an immediate and comprehensive review of strategic alternatives, specifically including the sale of its TMS business. This action escalates the activist campaign following Chernett's Schedule 13D filing on March 31st, which disclosed his significant ownership and intent to engage. Chernett asserts that a strategic separation of the TMS and clinic businesses could unlock substantial shareholder value, potentially 5-7 times the current stock price, citing a lack of synergy from the December 2024 Greenbrook acquisition. This puts considerable pressure on Neuronetics' board to evaluate a major restructuring, which could significantly impact the company's future direction and valuation. Investors will be closely watching the board's response and any further developments from Chernett.
At the time of this announcement, STIM was trading at $1.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $121.9M. The 52-week trading range was $0.80 to $4.85. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.